Modern views on the role of main components of stroma and tumor microinvironment in invasion, migration and metastasis
DOI:
https://doi.org/10.32471/exp-oncology.2312-8852.vol-42-no-4.15401Keywords:
activated fibroblasts, collagen, extracellular matrix, invasion, matrix metalloproteinases, metastasis, migration, myofibroblasts, tumor microenvironment, tumor progression, tumor-associated fibroblastsAbstract
Summary. The review presents modern ideas about tumor microenvironment, which most researchers recognize as the main “player” in tumor cell invasion, cell migration and metastasis. The current data on the main components of the stroma and the microenvironment, which play the role of the driving force in tumor progression, are analyzed. In particular, the review highlights the issues of origin, biological traits, phenotypic plasticity, functional heterogeneity of activated fibroblasts — myofibroblasts and tumor-associated fibroblasts, which in recent years have received much attention. Such components of the extracellular matrix proteome as collagen and matrix metalloproteinases are discussed in detail. They are mostly produced by activated fibroblasts and, on the one hand, initiate the development of desmoplasia due to type I collagen and, on the other hand, promote degradation of extracellular matrix proteins due to metalloproteinases, which generally leads to tissue remodeling that promotes tumor progression. Possibilities of using the most important indicators of extracellular matrix remodeling as potential markers and targets of clinical strategy are discussed.
References
Jayanthi V, Das AB, Saxena U. Grade-specific diagnostic and prognostic biomarkers in breast cancer. Genomics 2020; 112: 388–96.
Bertozzi S, Londero AP, Seriau L, et al. Biomarkers in Breast Cancer. 2018; Available from: https://cdn.intechopen.com/pdfs/62000.pdf.
Bu L, Baba H, Yoshida N, et al. Biological heterogeneity and versatility of cancer-associated fibroblasts in the tumor microenvironment. Oncogene 2019; 38: 4887–901.
Henke E, Nandigama R, Ergün S. Extracellular matrix in the tumor microenvironment and its impact on cancer therapy. Front Mol Biosci 2019; 6: 160.
Mnikhovich MV. Microenvironment of tumour cells in breast cancer: nature and types of interaction (ultrastructural study). Bull Volg GMU 2014; 2: 131–5 (in Russian).
Mnikhovich MV, Mishinа ES, Bezuglova ТВ, Bun’kov KV. Intercellular and cell-matrix interactions in breast carcinoma: the present state of problem. Tumors Female Reprod Syst 2018; 14: 20–7 (in Russian).
Brassart-Pasco S, Brézillon S, Brassart B, et al. Tumor microenvironment: extracellular matrix alterations influence tumor progression. Front Oncol 2020; 10: 397.
Nissen NI, Karsdal M, Willumsen N. Collagens and cancer associated fibroblasts in the reactive stroma and its relation to cancer biology. J Exp Clin Cancer Res. 2019; 38: 115.
Vong S, Kalluri R. The role of stromal myofibroblast and extracellular matrix in tumor angiogenesis. Genes Cancer. 2011; 2: 1139–45.
Tanjore H, Kalluri R. The role of type IV collagen and basement membranes in cancer progression and metastasis. Am J Pathol 2006; 168: 715–7.
Ricard-Blum S. The collagen family. Cold Spring Harb Perspect Biol 2011; 3: 1–19.
Zou Y, Zhang RZ, Sabatelli P, et al. Muscle interstitial fibroblasts are the main source of collagen VI synthesis in skeletal muscle: implications for congenital muscular dystrophy types Ullrich and Bethlem. J Neuropathol Exp Neurol 2008; 67: 144–54.
Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315: 1650–9.
Foster DS, Jones RE, Ransom RC, et al. The evolving relationship of wound healing and tumor stroma. JCI Insight 2018; 3: 99911.
Vasilenko IV, Kondratyuk RB, Bruk BB. Morphological features of the parenchymal-stromal interactions area in lung cancer with epithelial-mesenchymal transition. J Clin Exp Morphol 2013; 4: 18–21 (in Russian).
Rosivatz E, Becker I, Specht K, et al. Differential expression of the epithelial-mesenchymal transition regulators Snail, SIP1, and Twist in gastric cancer. Am J Pathol 2012; 161: 1881–91.
Peinado H, Quintanilla M, Cano A. Transforming growth factor beta-1 induces snail transcription factor in epithelial cell lines: mechanisms for epithelial mesenchymal transitions. J Biol Chem 2003; 278: 21113–23.
Rao S, Rao JPP, Jyothi BM, Varsha VK. Mysterious myofibroblast: A cell with diverse origin and multiple function. J Interdiscipl Histopathol 2017; 5: 12–7.
Xiong G-F, Xu R. Function of cancer cell-derived extracellular matrix in tumor progression. J Cancer Metastasis Treat 2016; 2: 357–64.
Öhlund D, Handly-Santana A, Biffi G, et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med 2017; 214: 579–96.
Gabbiani G. The evolution of myofibroblasts concept: A key cell for wound healing and fibrotic diseases. J Gerontol 2004; 52: 280–2.
Powell DW, Mifflin RC, Valentich JD, et al. Myofibroblasts. I. Paracrine cells important in health and disease. Am J Physiol 1999; 277: 1–9.
Hinz B, Phan SH, Thannickal VJ, et al. The myofibroblast: One function, multiple origins. Am J Pathol 2007; 170: 1807–16.
Hinz B. Formation and function of the myofibroblast during tissue repair. J Invest Dermatol 2007; 127: 526–37.
Chaudhar RB. Myofibroblasts: Functions, evolution, origins, and the role in disease. SRM J Res Dent Sci 2015; 6: 234–9.
Yavuz BG, Pestana RC, Abugabal YI, et al. Origin and role of hepatic myofibroblasts in hepatocellular carcinoma Oncotarget 2020; 11: 1186–201.
Najgebauer H, Liloglou T, Jithesh PV, et al. Integrated omics profiling reveals novel patterns of epigenetic programming in cancer-associated myofibroblasts Carcinogenesis 2019; 40: 500–12.
Liu Y. New insights into epithelial-mesenchymal transition in kidney fibrosis. J Am Soc Nephrol 2010; 21: 212–22.
Vered M, Dayan D, Yahalom R, et al. Cancer-associated fibroblasts and epithelial-mesenchymal transition in metastatic oral tongue squamous cell carcinoma. Int J Cancer 2010; 127: 1356–62.
Liu L, Lin L, Yao HH, et al. Stromal myofibroblasts are associated with poor prognosis in solid cancers: a meta-analysis of published studies. PLoS One 2016; 11: e0159947.
Luksic I, Suton P, Manojlovic S, et al. Significance of myofibroblast appearance in squamous cell carcinoma of the oral cavity on the occurrence of occult regional metastases, distant metastases, and survival. Int J Oral Maxillofac Surg 2015; 44: 1075–80.
Sinn M, Denkert C, Striefler JK, et al. α-Smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study. Br J Cancer 2014; 111: 1917–23.
Vered M, Shohat I, Buchner A, Dayan D. Myofibroblasts in stroma of odontogenic cysts and tumors can contribute to variations in the biological behavior of lesions. Oral Oncol 2005; 41: 1028–33.
Garg SV. Evaluation of stromal myofibroblasts expression in keratocystic odontogenic tumor and orthokeratinized odontogenic cysts: A comparative study. J Oral Maxillofac Pathol 2013; 17: 207–11.
Wang WQ, Liu L, Xu HX, et al. Intratumoral alpha-SMA enhances the prognostic potency of CD34 associated with maintenance of microvessel integrity in hepatocellular carcinoma and pancreatic cancer. PLoS One 2013; 8: e71189.
Kilvaer TK, Khanehkenari MR, Hellevik T, et al. Cancer associated fibroblasts in stage I-IIIA NSCLC: prognostic impact and their correlations with tumor molecular markers. PLoS One 2015; 10: e0134965.
Micallef L, Vedrenne NF, et al. The myofibroblast, multiple origins for major roles in normal and pathological tissue repair. Fibrogenesis Tissue Repair 2012; 5: S5.
Gascard P, Tlsty TD. Carcinoma-associated fibroblasts: orchestrating the composition of malignancy. Genes Dev 2016; 30: 1002–19.
Bauer M, Su G, Casper C, et al. Heterogeneity of gene expression in stromal fibroblasts of human breast carcinomas and normal breast. Oncogene 2010; 29: 1732–40.
Pidsley R, Lawrence MG, Zotenko E, et al. Enduring epigenetic landmarks define the cancer microenvironment. Genome Res 2018; 28: 625–38.
Glentis A, Oertle P, Mariani P, et al. Cancer-associated fibroblasts induce metalloprotease-independent cancer cell invasion of the basement membrane. Nat Commun 2017; 8: 1–13.
Shiga K, Hara M, Nagasaki T, et al. Cancer-associated fibroblasts: their characteristics and their roles in tumor growth. Cancers (Basel) 2015; 7: 2443–58.
Karagiannis GS, Poutahidis T, Erdman SE, et al. Cancer-associated fibroblasts drive the progression of metastasis through both paracrine and mechanical pressureon cancer tissue. Mol Cancer Res; 2012 10: 1403–18.
Wang K, Wu F, Seo BR, et al. Breast cancer cells alter the dynamics of stromal fibronectin-collagen interactions. Matrix Biol 2017; 60–61: 86–95.
D’Arcangelo E, Wu NC, Cadavid JL, McGuigan AP. The life cycle of cancer-associated fibroblasts within the tumour stroma and its importance in disease outcome. Br J Cancer 2020; 122: 931–42.
Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer 2016; 16: 582–98.
Pankova D, Chen Y, Terajima M, et al. Cancer-associated fibroblasts induce a collagen cross-link switch in tumor stroma. Mol Cancer Res 2016; 14: 287–95.
Hanley CJ, Noble F, Ward M, et al. A subset of myofibroblastic cancer-associated fibroblasts regulate collagen fiber elongation, which is prognostic in multiple cancers. Oncotarget 2016; 7: 6159–74.
Park BW, Oh JW, Kim JH, et al. Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes. Ann Oncol 2008; 19: 675–81.
Santi A, Kugeratski FG, Zanivan S. Cancer associated fibroblasts: the architects of stroma remodeling. Proteomics 2018; 18: e1700167.
Chen X, Song E. Turning foes to friends: Targeting cancer-associated fibroblasts affiliations. Nat Rev Drug Discov 2019; 18: 99–115.
Lai D, Ma L, Wang F. Fibroblast activation protein regulates tumor-associated fibroblasts and epithelial ovarian cancer cells. Int J Oncol 2012; 41: 541–50.
Kuperwasser C, Chavarria T, Wu M, et al. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci USA 2004; 101: 4966–71.
Wang L, Cao L, Wang H, et al. Cancer-associated fibroblasts enhance metastatic potential of lung cancer cells through IL-6/STAT3 signaling pathway. Oncotarget. 2017; 8: 76116–28.
Lim H, Moon A. Inflammatory fibroblasts in cancer. Arch Pharm Res 2016; 39: 1021–31.
Attieh Y, Clark AG, Grass C, et al. Cancer-associated fibroblasts lead tumor invasion through integrin-beta3-dependent fibronectin assembly. J Cell Biol 2017; 216: 1–12.
Lo A, Wang L-CS, Scholler J, et al. Tumor-promoting desmoplasia is disrupted by depleting FAP-expressing stromal cells. Cancer Res 2018; 75: 2800–10.
Cavaco ACM, Dâmaso S, Casimiro S, Costa L. Collagen biology making inroads into prognosis and treatment of cancer progression and metastasis. Cancer Metastasis Rev 2020; 39: 603–23.
Drifka CR, Loeffler AG, Mathewson K, et al. Highly aligned stromal collagen is a negative prognostic factor following pancreatic ductal adenocarcinoma resection. Oncotarget 2016; 7: 76197–213.
Fang M, Yuan J, Peng C, Li Y. Collagen as a double-edged sword in tumor progression. Tumor Biol 2014; 35: 2871–82.
Surowiak P, Murawa D, Materna V, et al. Occurence of stromal myofibroblasts in the invasive ductal breast cancer tissue is an unfavourable prognostic factor. Anticancer Res 2007; 27: 2917–24.
Katari SK, Pasala C, Nalamolu RM, et al. Pathophysiology of matrix metalloproteinases in breast cancer progression. J Clin Sci Res 2019; 8: 145–50.
Liotta LA, Tryggvason K, Garbisa S, et al. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980; 284: 67–8.
Kapoor C, Vaidya S, Wadhwan VH, et al. Seesaw of matrix metalloproteinases (MMPs). J Cancer Res Ther 2016; 12: 28–35.
Mannello F. Natural bio-drugs as matrix metalloproteinase inhibitors: New perspectives on the horizon? Recent Pat Anticancer Drug Discov 2006; 1: 91–103.
Krüger A, Arlt MJ, Gerg M, et al. Antimetastatic activity of a novel mechanism-based gelatinase inhibitor. Cancer Res 2005; 65: 3523–6.
Rudek MA, Venitz J, Figg WD. Matrix metalloproteinase inhibitors: Do they have a place in anticancer therapy? Pharmacotherapy 2002; 22: 705–20.
Sood AK, Fletcher MS, Coffin JE, et al. Functional role of matrix metalloproteinases in ovarian tumor cell plasticity. Am J Obstet Gynecol 2004; 190: 899–909.
Parks WC, Mecham RP. Matrix Metalloproteinases. San Diego, Calif: Academic Press 1998. 362 p.
Nagel H, Laskawi R, Wahlers A, Hemmerlein B. Expression of matrix metalloproteinases MMP-2, MMP-9 and their tissue inhibitors TIMP-1, -2, and-3 in benign and malignant tumours of the salivary gland. Histopathology 2004; 44: 222–31.
Kren L, Goncharuk VN, Krenová Z, et al. Expression of matrix metalloproteinase 3,10,11 (stromelysins 1, 2 and 3) and matrix metalloproteinase 7 (matrilysin) by cancer cells in non-small cell lung neoplasms. Clinicopathologic studies. Cesk Patol 2006; 42: 16–9.
Sogawa K, Kondo K, Fujino H, et al. Increased expression of matrix metalloproteinase-2 and tissue inhibitor of metallopro-teinase-2 is correlated with poor prognostic variables in patients with thymic epithelial tumors. Cancer 2002; 98: 1822–9.
Kumamoto H, Yamauchi K, Yoshida M, Ooya K. Immunohistochemical detection of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in ameloblastomas. J Oral Pathol Med 2003; 32: 114–20.
Mitani O, Katoh M, Shigematsu H. Participation of the matrix metalloproteinase inhibitor in Thy-1 nephritis. Pathol Int 2004; 54: 241–50.
Span PN, Sweep CG, Manders P, et al. Matrix metalloproteinase inhibitor reversion-inducing cysteine-rich protein with Kazal motifs: A prognostic marker for good clinical outcome in human breast carcinoma. Cancer 2003; 97: 2710–5.
Cui N, Hu M, Khalil RA. Biochemical and biological attributes of matrix metalloproteinases. Prog Mol Biol Transl Sci 2017; 147: 1–73.
Liu T, Zhou L, Li D, et al. Cancer-associated fibroblasts build and secure the tumor microenvironment. Front Cell Dev Biol 2019; 7: 60.
Nguyen XX, Muhammad L, Nietert PJ, Feghali-Bostwick C. IGFBP-5 promotes fibrosis via increasing its own expression and that of other pro-fibrotic mediators. Front Endocrinol 2018; 9: 601.
Kumar P, Smith T, Raeman R, et al. Periostin promotes liver fibrogenesis by activating lysyl oxidase in hepatic stellate cells. J Biol Chem 2018; 2: 12781–92.
Quintero-Fabián S, Arreola R, Becerril-Villanueva E, et al. Role of matrix metalloproteinases in angiogenesis and cancer. Front Oncol 2019; Available from: https://doi.org/10.3389/fonc.2019.01370.
Das A, Monteiro M, Barai A, et al. MMP proteolytic activity regulates cancer invasiveness by modulating integrins. Sci Rep 2017; 7: Available from: https://www.nature.com/articles/s41598-017-14340-w.
Li H, Qiu Z, Li F, Wang C. The relationship between MMP-2 and MMP-9 expression levels with breast cancer incidence and prognosis. Oncol Lett 2017; 14: 5865–70.
Alrehaili AA, Gharib AF, Karam RA. et al. Clinical significance of plasma MMP-2 and MMP-9 levels as biomarkers for tumor expression in breast cancer patients in Egypt. Mol Biol Rep 2020; 47: 1153–60.
Sarper M, Allen MD, Gomm J, et al. Loss of MMP-8 in ductal carcinoma in situ (DCIS)-associated myoepithelial cells contributes to tumour promotion through altered adhesive and proteolytic function. Breast Cancer Res 2017; 19: 33.
Chernov AV, Baranovskaya S, Golubkov VS, et al. Microarray-based transcriptional and epigenetic profiling of matrix metalloproteinases, collagens, and related genes in cancer. J Biol Chem 2010; 285: 19647–59.
Ramanujum R, Lin Y, Liu J, He S. Regulatory expression of MMP-8/MMP-9 and inhibition of proliferation, migration and invasion in human lung cancer A549 cells in the presence of HGF variants. Kaohsiung J Med Sci 2013; 29: 530–9.
Saito R, Miki Y, Ishida N, et al. The significance of MMP-1 in EGFR-TKI-resistant lung adenocarcinoma: Potential for therapeutic targeting. Int J Mol Sci 2018; 19: 609.
Pellinen T, Rantala JK, Arjonen A, et al. A functional genetic screen reveals new regulators of β1-integrin activity. J Cell Sci 2012; 125: 649–61.
Cheng J, Sauthoff H, Huang Y, et al. Human matrix metalloproteinase-8 gene delivery increases the oncolytic activity of a replicating adenovirus. Mol Ther 2007; 15: 1982–90.
Mok W, Boucher Y, Jain RK. Matrix metalloproteinases-1 and -8 improve the distribution and efficacy of an oncolytic virus. Cancer Res 2007; 67: 10664–8.
Zheng X, Goins BA, Cameron IL, et al. Ultrasound-guided intratumoral administration of collagenase-2 improved liposome drug accumulation in solid tumor xenografts. Cancer Chemother Pharmacol 2011; 67: 173–82.
Finke J, Ko J, Rini B, et al. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int Immunopharmacol 2011; 11: 853–8.
Ke S, Wang W, Qiu X, et al. Multiple target-specific molecular agents for detection and image analysis of breast cancer characteristics in mice. Curr Mol Med 2013; 13: 446–58.
Juurikka K, Butler GS, Salo T, et al. The role of MMP8 in cancer: A systematic review. Int J Mol Sci 2019; 20: E4506.
Soria-Valles C, Gutiérrez-Fernández A, Guiu M, Mari B, et al. The anti-metastatic activity of collagenase-2 in breast cancer cells is mediated by a signaling pathway involving decorin and miR-21. Oncogene 2014; 33: 3054–63.
Xu S, Xu H, Wang W, et al. The role of collagen in cancer: from bench to bedside. J Transl Med 2019; 17: 309.
Badaoui M, Mimsy-Julienne C, Saby C, et al. Collagen type 1 promotes survival of human breast cancer cells by overexpressing Kv10.1 potassium and Orai1 calcium channels through DDR1-dependent pathway. Oncotarget 2018; 9: 24653–71.
Liu J. Collagen 1A1 (COL1A1) promotes metastasis of breast cancer and is a potential therapeutic target. Discov Med 2018; 25: 211–23.
Theocharis AD, Manou D, Karamanos NK. The extracellular matrix as a multitasking player in disease. The FEBS J 2019; 286: 2830–69.
Ivarsson M, McWhirtera, Borg TK, Rubin K. Type I collagen synthesis in cultured human fibroblasts: regulation by cell spreading, platelet-derived growth factor and interactions with collagen fibers. Matrix Biol 1998; 16: 409–25.
Oxford JT, Doege KJ, Horton WE, Morris NP. Characterization of type II and type XI collagen synthesis by an immortalized rat chondrocyte cell line (IRC) having a low level of type II collagen mRNA expression. Exp Cell Res 1994; 213: 28–36.
Dolor A, Francis C. Szoka, Jr. Digesting a path forward — the utility of collagenase tumor treatment for improved drug delivery. Mol Pharm 2018; 15: 2069–83.
Tomko LA, Hill RC, Barrett A, et al. Targeted matrisome analysis identifies thrombospondin-2 and tenascin-C in aligned collagen stroma from invasive breast carcinoma. Sci Rep 2018; 8: 12941.
Meng C, He Y, Wei Z, et al. MRTF-A mediates the activation of COL1A1 expression stimulated by multiple signaling pathways in human breast cancer cells. Biomed Pharmacother 2018; 104: 718–28.
Wang J, Boddupalli A, Koelbl J, et al. Degradation and remodeling of epitaxially grown collagen fibrils. Cell Mol Bioeng 2019; 12: 69–84.
Zhurakovsky IP, Arkhipov SA, Arkhipova VV, et al. Collagens of types I and II in breast tumors. Modern Probl Sci Educ 2018; 5: 28098.
Zhou Z-H, Ji C-D, Xiao H-L, et al. Reorganized collagen in the tumor microenvironment of gastric cancer and its association with prognosis. J Cancer 2017; 8: 1466–76.
Jääskeläinen A, Jukkola A, Risteli J, et al. Elevated preoperative serum levels of collagen I carboxyterminal telopeptide predict better outcome in early-stage luminal-B-like (HER2-negative) and triple-negative subtypes of breast cancer. Tumour Biol 2019; 41: 1–9.
Fetah K, DiPardo BJ, Kongadzem EML, Tomlinson JS. Cancer Modeling-on-a-chip with future artificial intelligence integration. Small 2019; 15: 1901985.
Omer A, Maria P, Gal C, et al. Integrating artificial intelligence and nanotechnology for precision cancer medicine. Adv Mater 2020; 32: e1901989.
Oliver CR, Altemus MA, Westerhof TM, et al. A platform for artificial intelligence based identification of the extravasation potential of cancer cells into the brain metastatic niche. Electronic Supplementary Material(ESI) for Lab on a Chip. J Royal Soc Chem 2019; 7: c8lc01387.
Gole L, Yeong J, Lim JCT, et al. Quantitative stain-free imaging and digital profiling of collagen structure reveal diverse survival of triple negative breast cancer patients. Breast Cancer Res 2020; 22: 42.
Maiques O, Georgouli M, Sanz-Moreno V. Recent advances in tissue imaging for cancer research. Machine-learning and artificial intelligence. Version 1. F1000Res 2019; 8: F1000.
Liu Y, Tu H, You S, et al. Label-free molecular profiling for identification of biomarkers in carcinogenesis using multimodal multiphoton imaging. QIMS 2019; 9: 742–56
Talari ACS, Rehman S, Rehman IU. Advancing cancer diagnostics with artificial intelligence and spectroscopy: identifying chemical changes associated with breast cancer. Expert Rev Mol Diagn 2019; 19: 929–40.
Kistenev YuV, Vrazhnov DA, Nikolaev VV, et al. Analysis of collagen spatial structure using multiphoton microscopy and machine learning methods. Biochemistry (Moscow) 2019; 84: 108–23 (in Russian).
Qaiser T, Pugh M, Margielewska S, et al. Tumor-collagen digital proximity signature to indicate prognosis in diffuse large B-cell lymphoma. J Clin Oncol 2019; 37: e19073.
Zhang JK, He YR, Sobh N, Popescu G. Label-free colorectal cancer screening using deep learning and spatial light interference microscopy (SLIM). APL Photonics 2020; 5: 040805.
Kerner JK, Cleary A, Jain S, et al. Artificial intelligence powered predictive analysis of atypical ductal hyperplasia from digitized pathology images. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020; 80: Abstract P5-02-02.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
